Eli Lilly and Company (NYSE:LLY) will release its fourth-quarter financial results, before the opening bell, on Thursday, Feb. 6, 2025.

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per share in the year-ago period. Eli Lilly projects quarterly revenue of $13.43 billion, compared to $9.35 billion a year earlier, according to data from Benzinga Pro.

In January, just before the JP Morgan healthcare conference, Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.50 billion.

Eli Lilly shares gained 2% to close at $842.18 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• Wells Fargo analyst Mohit Bansal maintained an Overweight rating and cut the price target from $1,000 to $970 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.
• B of A Securities analyst Tim Anderson reinstated a Buy rating and a price target of $997 on Dec. 10, 2024. This analyst has an accuracy rate of 65%.
• Barclays analyst Carter Gould maintained an Overweight rating and cut the price target from $1,025 to $975 on Oct. 31, 2024. This analyst has an accuracy rate of 60%.
• Morgan Stanley analyst Terence Flynn reiterated an Overweight rating with a price target of $1,106 on Aug. 27, 2024. This analyst has an accuracy rate of 67%.
• BMO Capital analyst Evan Seigerman maintained an Outperform rating and raised the price target from $1,001 to $1,101 on Aug. 9, 2024. This analyst has an accuracy rate of 62%.

Considering buying LLY stock? Here’s what analysts think:

Read This Next:

• Jim Cramer: This Health Care Stock Is A ‘Winner,’ Buy Bitcoin Instead Of Coinbase